ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
雍和植髮(臨時代碼)
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
資料載入中...
總覽
公司
新聞
公告
康方生物-B(09926)免疫雙抗龍頭,國際化可期
华创证券
·
2021-01-29
港股醫藥股走強,藥明生物漲超5%,康方生物漲5.2%,康希諾生物漲4.4%...
新浪财经
·
2021-01-29
B類股成醫藥大跌重災區:康方生物跌超8% 啓明醫療跌7.9%
新浪港股
·
2021-01-27
配售融資:股價不跌反升的四個可能因素
新浪财经综合
·
2021-01-26
港股生物醫藥股拉昇走高,君實生物漲超10%,康希諾生物、康方生物等拉昇跟漲...
新浪财经
·
2021-01-25
港股異動丨醫藥B類股今日大漲,康方生物、再鼎醫藥等創新高
金融界
·
2021-01-20
康方生物-B漲近13%破頂 中生製藥漲近4%
智通财经网
·
2021-01-20
康方生物-B盤中異動 早盤股價大跌5.18%
自选股智能写手
·
2021-01-19
安信國際 | 康方生物(9926.HK):下一代抗體免疫治療領域新星
安信国际
·
2021-01-19
康方生物將以每股39.60港元的價格配售3000萬股新股,通過配股籌資11...
新浪财经
·
2021-01-07
09926--康方生物-B:根據一般授權配售新股
同花顺
·
2021-01-07
【港股通】康方生物(09926)折讓4.1-5.9%配股 籌資最多11.94億元
凤凰网港股
·
2021-01-06
大摩指康方生物(09926-HK)藥物名單豐富及研發引擎強勁 升目標價至43.5港元
财华社
·
2021-01-06
*大和升康方生物-B(09926)目標價33.3%至60港元 重申“買入”評級
凤凰网港股
·
2021-01-06
【券商聚焦】交銀國際:繼續看好研發能力較強的創新藥企 予中國生物製藥、康方生物及藥明生物“買入”評級
凤凰网港股
·
2021-01-06
【異動股】康方生物-B(09926-HK)漲3.29%
金融界
·
2021-01-04
上交所:對特定類型公司股票納入滬港通下港股通標的實施首次調整
新浪财经
·
2020-12-25
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/90010/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"90010","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90010\",,,,,undefined,":{"symbol":"90010","market":"HK","secType":"STK","nameCN":"雍和植髮(臨時代碼)","latestPrice":0,"timestamp":1747382400000,"preClose":0,"halted":8,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":0,"latestTime":"05-16 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747618200000},"marketStatusCode":5,"symbolChange":{"newSymbol":"09926","executeDate":"2020-04-14"},"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1747359000000,1747368000000],[1747371600000,1747382400000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90010\",,,,,undefined,":{"symbol":"90010","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"90010\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2107490682","title":"康方生物-B(09926)免疫雙抗龍頭,國際化可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2107490682","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2107490682?lang=zh_tw&edition=fundamental","pubTime":"2021-01-29 11:14","pubTimestamp":1611890072,"startTime":"0","endTime":"0","summary":"康方生物-B免疫双抗龙头,国际化可期 来源:华创证券中国生物药产业正在崛起。免疫双抗龙头进入收获期,AK104报产在即。公司是免疫双抗龙头公司,布局了多个产品,其中最快的PD-1/CTLA-4双抗和AK104已经启动了10多项临床试验。超过200例患者的大样本数据显示,AK104的安全性有望大幅优于PD-1+CTLA-4组合。在当前国内抗体药物竞争激烈的产业环境下,康方生物实现了差异化布局,商业化潜力巨大。同时,AK104和派安普利单抗等产品均有望实现国际化。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-29/doc-ikftssap1672396.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-29/doc-ikftssap1672396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["09926","90010"],"gpt_icon":0},{"id":"2107067249","title":"港股醫藥股走強,藥明生物漲超5%,康方生物漲5.2%,康希諾生物漲4.4%...","url":"https://stock-news.laohu8.com/highlight/detail?id=2107067249","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2107067249?lang=zh_tw&edition=fundamental","pubTime":"2021-01-29 09:36","pubTimestamp":1611884185,"startTime":"0","endTime":"0","summary":"港股医药股走强,药明生物涨超5%,康方生物涨5.2%,康希诺生物涨4.4%,药明康德涨2.5%,国务院办公厅发布关于推动药品集中带量采购工作常态化制度化开展的意见。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/7x24/2021-01-29/doc-ikftssap1639045.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/7x24/2021-01-29/doc-ikftssap1639045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["688185","159938","90010","02269","09926","09939"],"gpt_icon":0},{"id":"2106076734","title":"B類股成醫藥大跌重災區:康方生物跌超8% 啓明醫療跌7.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2106076734","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2106076734?lang=zh_tw&edition=fundamental","pubTime":"2021-01-27 10:24","pubTimestamp":1611714240,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 1月27日消息,医药股集体扑街,B类股成重灾区,康方生物跌超8%,启明医疗跌7.9%,康希诺跌近7%,再鼎医药跌6.3%,沛嘉医疗跌5%。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张海营","market":"us","thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-01-27/doc-ikftssap1231913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02500","159938","90010","09926","09939"],"gpt_icon":0},{"id":"2106427258","title":"配售融資:股價不跌反升的四個可能因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2106427258","media":"新浪财经综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2106427258?lang=zh_tw&edition=fundamental","pubTime":"2021-01-26 13:44","pubTimestamp":1611639846,"startTime":"0","endTime":"0","summary":"恒大汽车宣布配股后,股价昨日大升5成,报45.35元,创上市新高。其中,配售旧股涉及股东减持旧股,对股价较为不利。结果,在公司宣布配股当日,股价裂口大跌11.9%,现时于40.5元至46元水平横行近2个月,亦未能重上配股价。其股价至今累升41.6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/0ab00f49d2515ea77cf502014070887d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0ab00f49d2515ea77cf502014070887d"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/hkstock/ggscyd/2021-01-26/doc-ikftpnny1969354.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/hkstock/ggscyd/2021-01-26/doc-ikftpnny1969354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","01211"],"gpt_icon":0},{"id":"2106417309","title":"港股生物醫藥股拉昇走高,君實生物漲超10%,康希諾生物、康方生物等拉昇跟漲...","url":"https://stock-news.laohu8.com/highlight/detail?id=2106417309","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2106417309?lang=zh_tw&edition=fundamental","pubTime":"2021-01-25 09:36","pubTimestamp":1611538581,"startTime":"0","endTime":"0","summary":"港股生物医药股拉升走高,君实生物涨超10%,康希诺生物、康方生物等拉升跟涨。","market":"sh","thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/7x24/2021-01-25/doc-ikftssap0507146.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/7x24/2021-01-25/doc-ikftssap0507146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","688185","01877","09926","399441","161726","688180"],"gpt_icon":0},{"id":"2104010852","title":"港股異動丨醫藥B類股今日大漲,康方生物、再鼎醫藥等創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2104010852","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2104010852?lang=zh_tw&edition=fundamental","pubTime":"2021-01-20 10:40","pubTimestamp":1611110400,"startTime":"0","endTime":"0","summary":"华盛资讯1月20日消息,生物医药B类股今日大涨,康方生物、再鼎医药、荣昌生物等盘中创新高。截至发稿,启明医疗涨超11%,康方生物涨超9%,沛嘉医疗涨超8%,康希诺生物涨超6%,亚盛医药、再鼎医药涨超5%;荣昌生物、开拓药业等涨超3%,药明巨诺、加科思等涨超2%。相关资讯康方生物-B(09926)发布Cadonilimab联合化疗一线治疗晚期胃癌或胃食管结合部腺癌Ib/II期研究最新结果。花旗将再鼎医药目标价上调至216美元 加入重点观察名单。开拓药业GT90001联合Nivolumab治疗晚期肝癌II期临床研究亮相ASCO GI 2021。","market":"us","thumbnail":"https://static.tigerbbs.com/c318bcd91a109139b7d70c76c30bb154","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c318bcd91a109139b7d70c76c30bb154"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202101201150217c036926&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202101201150217c036926&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","09688","150131","09926","90010"],"gpt_icon":0},{"id":"2104610232","title":"康方生物-B漲近13%破頂 中生製藥漲近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2104610232","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2104610232?lang=zh_tw&edition=fundamental","pubTime":"2021-01-20 09:50","pubTimestamp":1611107400,"startTime":"0","endTime":"0","summary":"康方生物-B(09926)与中生制药(01177)共研产品发布最新研究结果。康方生物早盘高开高走,截至发稿,涨12.84%,报55.8港元,成交额1.2亿港元。中生制药涨3.93%,报7.66港元,成交额1.66亿港元。康方生物-B公告显示,公司与中国生物制药有限公司共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号:AK105)联合安罗替尼一线治疗晚期肝癌(“HCC”)的最新研究在2021年国际胃肠道癌症研讨会(“2021 ASCO GI”)上发布。","market":"hk","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202101201022087e5d9f9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202101201022087e5d9f9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["90010","01477","09926"],"gpt_icon":0},{"id":"2104476171","title":"康方生物-B盤中異動 早盤股價大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2104476171","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2104476171?lang=zh_tw&edition=fundamental","pubTime":"2021-01-19 10:16","pubTimestamp":1611022609,"startTime":"0","endTime":"0","summary":"2021年01月19日早盘10时16分,康方生物-B股票出现异动,股价急速跳水5.18%。康方生物-B股票所在的生物技术行业中,整体涨幅为2.78%。其相关个股中,君实生物、亚盛医药-B、方达控股涨幅较大,振幅较大的相关个股有莲和医疗、君实生物、亚盛医药-B,振幅分别为10.14%、8.58%、7.99%。消息层面,截至10时16分,《安信国际 | 康方生物:下一代抗体免疫治疗领域新星》资讯为影响康方生物-B的重要信息。因此,Cadonilimab有望成为全球首款获批的基于PD-1的双抗药物。","market":"hk","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202101191016517dc4cad9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202101191016517dc4cad9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["90010","09926"],"gpt_icon":0},{"id":"2104126991","title":"安信國際 | 康方生物(9926.HK):下一代抗體免疫治療領域新星","url":"https://stock-news.laohu8.com/highlight/detail?id=2104126991","media":"安信国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2104126991?lang=zh_tw&edition=fundamental","pubTime":"2021-01-19 10:08","pubTimestamp":1611022125,"startTime":"0","endTime":"0","summary":"有效性方面,AK104对于复发或转移性宫颈癌的ORR高达47.6%,而PD-1和CTLA-4单抗联合疗法或单药治疗的ORR在36.4%以下。因此,Cadonilimab有望成为全球首款获批的基于PD-1的双抗药物。基于自由现金流折现模型,我们预计康方生物的合理市值为443.98亿港元,即每股56.41港元。此报告所载的资料、意见及推测反映安信国际于最初发此报告日期当日的判断,可随时更改而毋须另行通知。安信国际保留一切权利。","market":"sh","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-19/doc-ikftpnnx9184643.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-19/doc-ikftpnnx9184643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","09926"],"gpt_icon":0},{"id":"2101605415","title":"康方生物將以每股39.60港元的價格配售3000萬股新股,通過配股籌資11...","url":"https://stock-news.laohu8.com/highlight/detail?id=2101605415","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2101605415?lang=zh_tw&edition=fundamental","pubTime":"2021-01-07 07:51","pubTimestamp":1609977101,"startTime":"0","endTime":"0","summary":"康方生物将以每股39.60港元的价格配售3000万股新股,通过配股筹资11.9亿港元。","market":"us","thumbnail":"https://static.tigerbbs.com/60ffa9c348f2ccdef831ec338d80994f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/60ffa9c348f2ccdef831ec338d80994f"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-01-07/doc-iiznezxt0973101.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-01-07/doc-iiznezxt0973101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["09926","90010"],"gpt_icon":0},{"id":"2101239602","title":"09926--康方生物-B:根據一般授權配售新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2101239602","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2101239602?lang=zh_tw&edition=fundamental","pubTime":"2021-01-07 07:48","pubTimestamp":1609976939,"startTime":"0","endTime":"0","summary":"09926--康方生物-B:根據一般授權配售新股 来源:联交所--披露易香港交易及結算所有限 公司及香港聯合交易所 有限公司對本公告的內 容概不負責,對其準確性或完整性亦不發 表任何聲明,並明 確表示,概不對因本 公告全部或任何 部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責 任。配 售 股份 將根據一般 授權配發 及發行 ,無需股 東批准。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-07/doc-iiznezxt1090401.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-07/doc-iiznezxt1090401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","09926"],"gpt_icon":0},{"id":"2101247936","title":"【港股通】康方生物(09926)折讓4.1-5.9%配股 籌資最多11.94億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2101247936","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2101247936?lang=zh_tw&edition=fundamental","pubTime":"2021-01-06 17:38","pubTimestamp":1609925881,"startTime":"0","endTime":"0","summary":"原标题:【港股通】康方生物(09926)折让4.1-5.9%配股 筹资最多11.94亿元 来源:凤凰网港股凤凰网港股|康方生物(09926)折让4.1-5.9%配3000万股筹最多11.94亿元。","market":"sh","thumbnail":"https://static.tigerbbs.com/28009f8e87ba9680b5b94d59ba7ac119","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/28009f8e87ba9680b5b94d59ba7ac119"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznctkf0484379.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznctkf0484379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["09926","90010"],"gpt_icon":0},{"id":"2101962479","title":"大摩指康方生物(09926-HK)藥物名單豐富及研發引擎強勁 升目標價至43.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2101962479","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2101962479?lang=zh_tw&edition=fundamental","pubTime":"2021-01-06 09:57","pubTimestamp":1609898233,"startTime":"0","endTime":"0","summary":"原标题:大摩指康方生物(09926-HK)药物名单丰富及研发引擎强劲 升目标价至43.5港元 来源:财华社【财华社讯】大摩发布报告指康方生物(09926-HK)药物名单丰富及研发引擎强劲,升其目标价至43.5港元,给予增持评级。该公司股价现报43.2港元,涨0.47%,成交量26.70万,成交额1159.47万港元。","market":"sh","thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznctkf0395839.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznctkf0395839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["09926","90010"],"gpt_icon":0},{"id":"2101624760","title":"*大和升康方生物-B(09926)目標價33.3%至60港元 重申“買入”評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2101624760","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2101624760?lang=zh_tw&edition=fundamental","pubTime":"2021-01-06 08:48","pubTimestamp":1609894125,"startTime":"0","endTime":"0","summary":"原标题:*大和升康方生物-B(09926)目标价33.3%至60港元 重申“买入”评级 来源:凤凰网港股凤凰网港股|大和将康方生物-B(09926)目标价由45港元提升至60港元,重申“买入”评级。","market":"us","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznctkf0376478.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznctkf0376478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["09926","90010"],"gpt_icon":0},{"id":"2101864220","title":"【券商聚焦】交銀國際:繼續看好研發能力較強的創新藥企 予中國生物製藥、康方生物及藥明生物“買入”評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2101864220","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2101864220?lang=zh_tw&edition=fundamental","pubTime":"2021-01-06 08:29","pubTimestamp":1609892998,"startTime":"0","endTime":"0","summary":"119种药品谈判成功,平均降幅50.64%,今年3月1日起正式实施。交银认为,创新品种进入医保谈判的速度和数量显著提升,继续看好研发能力强的创新药企及CRO企业,包括中国生物制药、康方生物和药明生物。","market":"sh","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznezxt0790682.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-01-06/doc-iiznezxt0790682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","01177","02269","09926","90014","03329","159992","06978"],"gpt_icon":0},{"id":"2100668897","title":"【異動股】康方生物-B(09926-HK)漲3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2100668897","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2100668897?lang=zh_tw&edition=fundamental","pubTime":"2021-01-04 11:45","pubTimestamp":1609731924,"startTime":"0","endTime":"0","summary":"原标题:【异动股】康方生物-B(09926-HK)涨3.29% 来源:财华网【财华社讯】康方生物-B(09926-HK)截至11:45上涨3.29%,现报39.25港元,涨1.25港元。成交262万股,涉资1.024亿元。(出处:FinetAI)","market":"sh","thumbnail":"https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2021-01-04/doc-iiznezxt0468944.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2021-01-04/doc-iiznezxt0468944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","09926"],"gpt_icon":0},{"id":"2094755518","title":"上交所:對特定類型公司股票納入滬港通下港股通標的實施首次調整","url":"https://stock-news.laohu8.com/highlight/detail?id=2094755518","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2094755518?lang=zh_tw&edition=fundamental","pubTime":"2020-12-25 20:37","pubTimestamp":1608899820,"startTime":"0","endTime":"0","summary":"12月25日消息,上交所:对特定类型公司股票纳入沪港通下港股通标的实施首次调整,调入康方生物等三只股票。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张熠","market":"us","thumbnail":"https://static.tigerbbs.com/1ff2485e9c1a5379b1ab137edc2fbd50","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1ff2485e9c1a5379b1ab137edc2fbd50"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2020-12-25/doc-iiznezxs8935315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["90010"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":112,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/90010\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2020-04-14","symbol":"90010","oldSymbol":"90010","newSymbol":"09926","exchange":"SEHK","type":"symbolChange","dateTimestamp":1586793600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"90010\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"90010\",market:\"HK\",delay:false,,,undefined,":{}}}